NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Insmed Incorporated (INSM) Stock Analysis

Insmed Incorporated (INSM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INSM

$94.04

−$1.63 (−1.70%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INSM with… →

INSM Key Statistics

As of Oct 21, 2026
Trading
Open
$95.09
Previous Close
$95.67
Day's Range
93.80–97.08
52-Week Range
90.39–212.75
Volume
2.95M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.82
Valuation
Market Cap
$20.54B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
112.74
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.05
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.12
Financials (FY)
Revenue (FY)
$606.42M+66.73%
Net Income (FY)
−$1.28B
Profit marginThe share of revenue left as profit after all costs and taxes.
−76.94%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
218.38M
1-Year Return
−43.11%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
2.62M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INSM closed at $94.04, −43.11% over 1 year.

Insmed Incorporated (INSM) has a market capitalization of $20.54B.

In fiscal 2025, INSM reported revenue of $606.42M.

INSM Stock Return by Calendar Year

Insmed Incorporated (INSM) 10-year return: what $10,000 became

1 year
$10,000 $5,689
−43.11%
5 years
$10,000 $34,172
+241.72%
10 years
$10,000 $66,980
+569.80%

If you had invested $10,000 in Insmed Incorporated (INSM) 10 years ago, at the close on October 21, 2016, it would have been worth $66,980 at the close on October 21, 2026: +569.80% in total, +20.95% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−45.97%
2025+152.09%
2024+122.78%
2023+55.11%
2022−26.65%
2021−18.17%
2020+39.41%
2019+82.01%
2018−57.92%
2017+135.68%
2016 (partial year)+13.37%

As of October 21, 2026.

INSM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$606.42M−$1.28B−210.5%
2024$363.71M−$913.77M−251.2%
2023$305.21M−$749.57M−245.6%
2022$245.36M−$481.53M−196.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$606.42M$483.49M−$994.78M−$1.28B−210.5%
2024$363.71M$277.97M−$786.57M−$913.77M−251.2%
2023$305.21M$239.64M−$680.93M−$749.57M−245.6%
2022$245.36M$190.23M−$478.12M−$481.53M−196.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INSM Valuation vs Biotechnology Median

Median of 608 stocks
MetricINSMBiotechnology medianvs median
P/S ratio18.0513.3036% above
Profit margin−76.94%−38.31%38.6 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Insmed Incorporated (INSM) at $20.54B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 1,664 employees.

INSM last closed at $94.04 on October 21, 2026. That is −$1.63 (−1.70%) against the previous close. Over the past 52 weeks the price has ranged from $90.39 to $212.75. The latest close sits 4.04% above that 52-week low.

Financial Health

In fiscal 2025, Insmed Incorporated reported revenue of $606.42M. That is +66.73% against the prior fiscal year, when revenue was $363.71M. The same year closed with a net loss of $1.28B. The reported profit margin is −76.94%. That is 38.6 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −4.12.

Across the 4 fiscal years on file, revenue moves from $245.36M in 2022 to $606.42M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 112.74. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.09. Measured against sales, the shares trade at 18.05 times revenue. On price-to-sales that is 35.74% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −43.11%. Measured over 10 years, that is +20.95% a year compounded. Beta against the wider market is reported at 0.82. Annualized volatility over the trailing 10 years is 79.07%.

Growth & Income

No dividend is on file for INSM.

The strongest complete calendar year on file is 2025 at +152.09%; the weakest is 2018 at −57.92%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the total return is −45.97% year to date.

Peer Comparison

Insmed Incorporated (INSM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Insmed Incorporated INSM $20.54B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Insmed Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Insmed Incorporated

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Visit website →